Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230040/S034

Cordella Pulmonary Artery Sensor System (CorPASS)

Endotronix, Inc. · Decision date Oct 14, 2026

MEDTECHLEDGER EXPLANATIONP230040/S034

What did the FDA decide?

The FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-14, for P230040/S034, a supplement to the Cordella Pulmonary Artery Sensor System (CorPASS) held by Endotronix, Inc. The supplement falls under the process change category covering manufacturer, sterilizer, packager or supplier, and the recorded statement describes automating an incoming functional inspection test method. The device is listed in the implantable hemodynamic system category within cardiovascular devices, product code MOM.

The notice addresses a manufacturing test-method change rather than a new approval of the CorPASS system as a whole; the underlying original approval and its clinical labeling are not restated here. The source record includes no documents, so the specific test method, affected manufacturing site and any inspection performance data remain unknown. Whether the automation alters inspection sensitivity or acceptance criteria cannot be determined from the available fields.

Readers should treat OK30 as the recorded decision on this supplement only. No clinical, efficacy or patient-selection conclusions follow from a process change of this kind, and none are asserted here.

FDA approval order statement

automating an incoming functional inspection test method
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 14, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230040/S034
Regulatory pathway
PMA supplement
Product code
MOM
Decision code
OK30
Decision date
Oct 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, hemodynamic, implantable.

Product code
MOM
FDA device class
3

For the original device and its historical approval scope, see PMA P230040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230040 · Original PMA

    Cordella Pulmonary Artery Sensor System (CorPASS)

  2. P230040/S034 received

    Application receipt date recorded by FDA.

  3. P230040/S033 · Related supplement

    Cordella Pulmonary Artery Sensor System (CorPASS)

  4. P230040/S034 · FDA decision

    30-Day Notice

  5. P230040/S031 · Related supplement

    Cordelia Pulmonary Artery Pressure Sensor System (CorPASS)

  6. P230040/S035 · Related supplement

    Cordella Pulmonary Artery Sensor System (CorPASS)

  7. P230040/S030 · Related supplement

    Cordella Pulmonary Artery Sensor System

Timeline entries are records held by MedtechLedger for P230040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230040

Product / regulatory recordCompanyPathwayDecision dateSource
Endotronix, Inc.PMA approvalJun 20, 2024FDA
Endotronix, Inc.PMA supplementSep 25, 2026FDA
Endotronix, Inc.PMA supplementOct 16, 2026FDA
Endotronix, Inc.PMA supplementOct 20, 2026FDA
Endotronix, Inc.PMA supplementOct 29, 2026FDA

Explore the linked device profile

Other records with product code MOM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Endotronix, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1415 W. Diehl Rd., Suite 500w, Naperville, IL, 60563

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records